Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
In June 2022, CLL Society penned a letter to the FDA that received signatures of support from 40 of the top CLL / SLL physicians in the country.
Chairman of the Board and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the final results of a phase 1/2 clinical trial of entospletinib combined with obinutuzumab in patients with relapsed/refractory CLL.
During the first quarter of 2022, CLL Society conducted a survey among our CLL / SLL community about barriers to care relating to health insurance, finances, and geographic barriers. There were 130 respondents.
Discussion of a new monoclonal antibody, ianalumab (previously known as VAY736), targeting the B-cell activating factor (BAFF) receptor. We refer to the compound as VAY736 for consistency with the interview and abstract for this article.
We discussed the nature of the immune deficiencies associated with CLL / SLL and how one might remediate a significant part of the problem.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and
Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.
Expert Access Data Confidentiality Disclosure Expert Access Data Confidentiality Disclosure The Expert Access Program is being provided by CLL Society, a 501c3 nonprofit organization. The CLL Society is focused on patient
TG Therapeutics, after a decade of development, is withdrawing its application for the combination of ublituximab and UKONIQ (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
One click to our most popular content.
